Interferons (IFNs) have been investigated as important cytokines in immunotherapy. The use of IFNs in cancer immunotherapy has had limited success. In this study, IFN genes were delivered into B16 melanoma cells by lentiviral vectors, and their effects on B16 melanoma were comprehensively analyzed. Type II IFN significantly impaired the viability of B16 cells in vitro. Expression of IFNa and IFNb in B16 cells efficiently suppressed the establishment of inoculated melanoma. However, intratumoral delivery of IFNs alone with lentiviral vectors had no therapeutic effects on established melanoma. To address the lack of response, a lentivector was constructed to simultaneously transfer therapeutic genes and small interfering RNAs (siRNAs). IFNs and siRNA targeting signal transducer and activator of transcription 3 (STAT3), which is a major immune suppressive transcription factor in melanoma, were delivered simultaneously into the tumor milieu. This treatment successfully rescued the response to IFNg and attenuated the growth of established tumors. This method has the potential to improve the therapeutic effects of IFNs in cancer immunotherapy.
INTRODUCTION
The relationship between tumors and the immune system has been studied for over a century. Recent research has suggested the possibility of cancer immunoediting. 1 Immunotherapy has become a potential method for cancer treatment.
2 Interferons (IFNs) are important cytokines in the immune system and play a pivotal role in cancer immunoediting. The functions of type I (IFNa and IFNb) and type II IFNs (IFNg) in tumor progression have been previously described. [3] [4] [5] IFNs activate immune cells (for example, natural killer cells, dendritic cells, T cells and B cells), promote tumor cell apoptosis and inhibit angiogenesis. 6 IFNs have been clinically used to treat a diverse range of tumors. 7 However, the effects of IFNs in a clinical setting have not been adequately described.
Signal transducer and activator of transcription 3 (STAT3) is an important transcription factor in immune suppression. STAT3 transduces signals in numerous oncogenic pathways and activates many genes in tumorigenesis, including myc, surviving, vascular endothelial growth factor and more. [8] [9] [10] It also inhibits the production of proinflammatory factors. 11 In various cancers, STAT3 is constitutively activated in tumor cells and tumor-infiltrating immune cells. 12 Activated STAT3 strengthens the function of immune suppression cells, such as regulatory T cells, 13, 14 which are important for maintaining an immune suppression environment in the tumor milieu. Moreover, hyperactive STAT3 attenuates the antitumor effects of IFNs. 15 Inhibition of hematopoietic STAT3 has been shown to elicit antitumor immunity in tumor-bearing mice. 13 STAT3 has become an attractive target in cancer immunotherapy.
Lentiviral vectors are promising tools for in vivo gene delivery. 16 They can stably transduce nondividing cells and mediate longterm gene expression. Lentivectors have been used in a clinical setting and provide benefits in patients with diseases that are caused by gene deficiencies. 17 In cancer research, lentivectors are often used to elicit tumor antigen-specific immune responses or transfer therapeutic genes via intratumoral injection. 18, 19 In the present study, IFNs were delivered into B16 melanoma cells using lentiviral vectors. Compared with type I IFNs, IFNg remarkably suppressed tumor cell growth in vitro. However, type I IFNs effectively inhibited the establishment of inoculated tumors. Intratumoral administration of IFNs alone using lentiviral vectors did not attenuate the growth of aggressive melanoma. To improve the effects of IFNs, we constructed a lentiviral vector to coexpress IFN genes and small interfering RNA (siRNA) targeting STAT3. Simultaneous administration of IFNs and siRNA with this vector significantly suppressed the growth of established B16 melanoma. This study describes a potential method for surmounting unresponsiveness to cancer immunotherapy treatment.
MATERIALS AND METHODS

Cell lines and mice
The 293FT cell line was purchased from Invitrogen (Shanghai, China) and cultured in Dulbecco's modified Eagle's media containing 10% (v/v) fetal bovine serum and 1% (v/v) penicillin/streptomycin. The B16 melanoma cell line was purchased from ATCC (Manassas, VA, USA) and cultured in RPMI-1640 supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) penicillin/streptomycin. All cells were grown at 37 1C in an incubator with a humidified atmosphere of 5% CO 2 .
C57BL/6 mice were fed under specific pathogen-free conditions at the Animal Center at the Third Military Medical University. For all experiments, 8-to 12-week-old mice were used.
shown in Figure 1 . The expression of IFNs was driven by cytomegalovirus immediate-early gene promoter (CMV). To downregulate STAT3, three shRNAs targeting the CDS of STAT3 were designed (http://katahdin.cshl. org) and subcloned into a miR30 cassette by EcoRI and XhoI to generate FUGshSTAT3W. The RNA interference (RNAi) efficiency was measured by western blot and the shRNA with the highest interference effectiveness was used in the following experiments. The lentiviral vector FUIFNsh-STAT3W was constructed to simultaneously deliver IFNs and siRNA by replacing the green fluorescent protein (GFP) in FUGshSTAT3W with IFN genes. All plasmids were verified by DNA sequencing.
Production of lentiviruses HIV-1-based lentiviral particles were prepared by co-transfecting three plasmids into 293FT cells, including pMD2.G, psPAX2 and lentivectors. 20 All of the viruses were pseudotyped with a vesicular stomatitis viral G protein. Viral solutions were concentrated using ultracentrifugation. The titers of lentiviral vectors with GFP were determined using fluorescence-activated cell sorting. The titers of vectors without fluorescence markers were detected using quantitative PCR. 20 Quantitative PCR Total RNA was extracted from cells with TRIzol reagent (Invitrogen, Shanghai, China). Complementary DNA was synthesized using the PrimeScript RT reagent kit (Takara, Dalian, China). Each sample was amplified for IFNs and actin using the SYBR Premix DimerEraser (Takara). PCR was performed on an ABI 7300 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). The relative expression levels were calculated using the DDCt method. All primers are listed in Table 1 .
Western blot
The total protein was prepared from the cells using RIPA lysis buffer (Beyotime, Shanghai, China). Western blot was performed following the standard method. An anti-STAT3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
In vitro B16 growth assessment
A total of 1.5 Â 10 4 B16 cells per well were plated on a 12-well plate 6 h before transduction. Lentivectors expressing the IFN genes were added into the wells at a multiplicity of infection of 20. After 24 h, the supernatant was replaced with fresh culture medium. At 24, 48 and 72 h after adding Tumor treatment using lentiviral vectors Before treatment, the mice were anesthetized with pentobarbital sodium solution. A total of 5 ml of the lentivirus (2 Â 10 8 TU ml À 1 ) was slowly injected into the center of the lesion. The needle was held stationary for 2 min and pulled out rapidly to avoiding leaking. The tumor volume of the treated mice was measured every 2 days.
Statistics
Student's t-test and analysis of variance were used to determine statistical significance. A P-value of o0.05 was considered significant.
RESULTS
Delivery of IFNs by lentiviral vectors suppressed B16 growth in vitro
The coding sequences of the IFN genes were cloned by PCR and inserted into lentiviral vectors to generate vectors that overexpressed IFNa, b and g (Figure 1a ). The corresponding virus was prepared using the calcium phosphate transfection method. To evaluate the function of the vectors, 293FT cells were transduced by the viruses and the mRNA of the IFNs was measured using quantitative PCR. The transcription levels of the IFNs were greatly increased after transduction by IFN-expressing vectors compared with the control vector (Figure 1b) . The virus was used to transfer the IFN genes into the B16 cells. Although the GFP intensity was low, over 95% of the B16 cells were successfully transduced (Figure 1c Simultaneous delivery of IFNs and shRNA-STAT3 using lentiviral vectors attenuated the growth of established B16 melanoma To coadminister IFNs and shRNA, the GFP in FUGshSTAT3W was replaced with IFNa, IFNb and IFNg, respectively (Figure 5a ). The tumor-bearing mice were injected intratumorally with the lentiviral vectors twice at specific time points. FUIFNashSTAT3W and FUIFNbshSTAT3W did not exhibit antitumor effects. However, FUIFNgshSTAT3W markedly repressed the growth of established tumors and elongated the survival of tumor-bearing mice (FUIFNgshSTAT3W vs FUGW, Po0.05; Figures 5b and c) , although it did not induce tumor regression in this study. shRNA targeting STAT3 successfully reversed the lack of response to lentiviralmediated IFNg treatment compared with IFNs alone.
DISCUSSION
Evading immune destruction is a hallmark of cancer. 21 IFNs have been recognized as key molecules in cancer immunoediting. IFNdeficient mice are more prone to developing tumors than wildtype mice. 3, [22] [23] [24] The antitumor activities of IFNs have been widely described in mouse models. However, the effects of IFNs in a clinical setting have not been as positive as expected. 25, 26 Longer survival times resulting from treatment with IFNa are often accompanied by autoimmunity. More importantly, treatment with IFNg is not beneficial in patients with certain tumors. 27, 28 The local immunosuppressive microenvironment may contribute to the lack of response to cancer immunotherapy. In this study, delivery of type I or II IFNs using lentivectors into established tumors did not inhibit tumor growth. In another study, It is more difficult to produce large amounts of lentiviral particles compared with adenoviruses. As a result, incomplete delivery is a likely explanation for the lack of response to the intratumoral injection of lentiviral vectors expressing IFN in this study.
Because STAT3 is pivotal in maintaining immune suppression of tumors, the antitumor effects of IFNs may be rescued by counteracting the abnormal activities of STAT3 in the tumor microenvironment. Inhibition of p-STAT3 has been demonstrated to enhance the antitumor effects of systemic delivery of IFNa. 15 We constructed a lentiviral vector to simultaneously deliver IFNs and siRNA targeting STAT3. As expected, downregulating STAT3 rescued the effect of IFNg, leading to attenuation of the growth of the established tumor. This result indicates that the clinical benefits of immune-stimulating therapy may need breaking tumor-induced immune suppression simultaneously.
Systemic delivery of IFNs often causes serious side effects, such as fever and autoimmunity. 30 Local and targeted delivery of genes to tumor lesions is a promising approach to increase the safety and efficiency of treatment. Intratumoral injection of viruses carrying different therapeutic genes is commonly performed. Compared with adenovectors, lentivectors have lower immunogenicity and can generate gene expression for longer periods of time. Lentivectors efficiently transduce dendritic cells, which are major antigen-presenting cells in vivo. 18 Injection of lentiviral vectors carrying tumor-associated antigens elicits robust antitumor immune responses. 31 The transfer of genes into a tumor using lentiviral vectors may be a potential tool in cancer immunotherapy. We used a cassette consisting of miR30-based RNAi, which was first described by Elledge and colleagues. 32 In this vector, ectopic genes and siRNA expression are co-driven by same Pol II promoter. An advantage of the vector is that the GFP upstream of the miR30 cassette can be replaced with other genes, such as IFNs, GM-CSF and TNFa. The miR30-based RNAi cassette can be used in tandem to downregulate several genes simultaneously. 33 This is a powerful, convenient platform for coupling different therapeutic genes and siRNAs. The antitumor effects of additional genes may be unmasked using this vector, as was shown for IFNg in this study. In contrast to the results of this study, delivery of IFNb alone by an adenovirus was shown to eradicate an established tumor. Simultaneous delivery of immune activators and inhibition of immunosuppressive molecules may be a promising method for breaking down tumors with immune suppression. In other studies that treated murine B16 melanoma, IFNs have been co-administered with other therapeutics. Combination therapy using IFNa and dacarbazine (DTIC) significantly suppressed tumor growth compared with DTIC alone. 35 The combination of tumor-targeted superantigens with IFNa exhibited synergistic antitumor effects in a B16 metastasis lung tumor model. 36 Administration of CpG with IFNa provoked superior antitumor responses in an intraperitoneal model of B16 melanoma compared with each agent alone. 37 In particular, administration of an IFNa-expressing vector with WP1193, which is an inhibitor of STAT3 signaling, showed synergistic effects against metastasis and intracerebral melanoma. This combination treatment inhibited leptomeningeal disease and enhanced the antitumor cytotoxicity of natural killer cells and T cells. 15 Consistent with our results, these studies emphasized the superiority of combination therapy in treating murine melanoma and demonstrated several mechanisms of these effects. The vectors used in this study are more suitable for restricting therapeutic molecules in a tumor microenvironment compared with systemic administration, which enhances the therapeutic efficacy and reduces side effects.
IFNa prevented tumor establishment, but could not suppress the growth of an established tumor. IFNg with siRNA targeting STAT3 most efficiently inhibited the growth of established tumors. IFNg was recently shown to be the link between radiation and melanomagenesis in mice. 38 Low levels of IFNg promote tumor development, whereas high levels exhibit antitumor activity. 39 The effects of IFNs on tumors depend on the concentration of IFN and the stage of the tumor growth. These phenomena should be further studied to develop additional treatment modalities.
In this study, we simultaneously assessed the effects of IFNs on B16 cells in vitro and in vivo. Delivery of IFNs alone using lentiviral vectors did not efficiently inhibit tumor growth in vivo. Using a novel vector, IFNs and siRNA targeting STAT3 were simultaneously transferred into the tumor milieu. Delivery of IFNg with siRNA attenuated the growth of B16 melanoma. The method described in this study provides a useful tool for cancer immunotherapy by integrating the advantages of lentivectors in genetic immunization and the simultaneous effects of co-delivering genes and siRNAs. By altering the genes and siRNAs in this plasmid, it will be possible to develop lentivectors with promising antitumor effects in cancer immunotherapy.
